Latest news with #Biomedical
Yahoo
3 days ago
- Business
- Yahoo
PECA Labs' Dr. Arush Kalra Named to Pittsburgh's 40 Under 40 List
Biomedical innovator recognized for advancing next-generation cardiovascular devices and making a lasting impact on patients' lives PITTSBURGH, August 18, 2025--(BUSINESS WIRE)--PECA Labs, a medical device company redefining the field of vascular grafts and valves with durable, polymeric cardiovascular devices designed to fit, grow, and last, today announced that Co-founder and Chief Scientific Officer Dr. Arush Kalra has been named to the Pittsburgh 40 Under 40 list by Pittsburgh Magazine and PUMP. The Pittsburgh 40 Under 40 awards honor high-performing, high-impact professionals who are driving innovation and strengthening the Pittsburgh community through leadership, professional excellence, and service. Dr. Kalra leads PECA Labs' scientific and engineering programs, overseeing clinical research and the development of its proprietary tunable polymeric material platform for cardiovascular implants. Inspired by his mother's battle with cardiovascular disease, he began his career in medicine before pivoting to medical device innovation at the encouragement of a mentor. While pursuing his Master of Science in Biomedical and Medical Engineering at Carnegie Mellon University (CMU), he co-founded PECA Labs with fellow CMU Tartans Doug Bernstein and Jamie Quinterno—without whom, he notes, the venture would not have been possible—to advance the field of cardiothoracic surgery. Since 2018, Dr. Kalra has also served as an adjunct professor at the University of Pittsburgh. "This recognition carries profound meaning, as it brings much-needed attention to the challenges faced by families confronting congenital cardiac defects and chronic adult cardiovascular diseases," said Dr. Kalra. "Our mission is simple yet powerful: to develop innovative cardiovascular devices that provide patients with an improved quality of life and the chance to grow, thrive, and avoid repeat surgeries. It is an honor to be recognized alongside so many talented individuals who are making a meaningful impact in the Pittsburgh community—a place that has given so much to us at PECA Labs and continues to inspire our work." In 2024, PECA Labs opened a new polymeric processing facility near its headquarters in Pittsburgh's Bloomfield neighborhood, adjacent to UPMC Children's Hospital. This expansion brings critical manufacturing in-house, giving the company greater control over production, faster scalability, and the ability to meet growing demand. About PECA Labs PECA Labs is reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last—helping patients avoid repeat surgeries while reducing morbidity and mortality. The company's proprietary technologies, including a controllably expandable graft and low-thrombosis polymeric membrane, are built on a tunable polymer platform that delivers greater durability, customization, and biocompatibility than current cardiovascular implants. PECA's devices resist thrombosis, calcification, and immune response, while offering growth potential, customization, and noninvasive visualization. For more information, visit View source version on Contacts Media Contact: Joe DuraesPazanga Health Communicationsjduraes@ (917) 687-6419
Yahoo
01-08-2025
- Business
- Yahoo
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +28.76%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.92 per share when it actually produced a loss of $2.52, delivering a surprise of +13.7%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Moderna, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $142 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.66%. This compares to year-ago revenues of $241 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Moderna shares have lost about 28.9% since the beginning of the year versus the S&P 500's gain of 7.8%. What's Next for Moderna? While Moderna has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Moderna was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.87 on $1.11 billion in revenues for the coming quarter and -$10.05 on $2.08 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Adaptive Biotechnologies (ADPT), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 5. This life-sciences research company is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +7.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Adaptive Biotechnologies' revenues are expected to be $49.7 million, up 15.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA) : Free Stock Analysis Report Adaptive Biotechnologies Corporation (ADPT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
CTV News
23-07-2025
- Health
- CTV News
‘Youth inspiring youth': The summer camp giving Manitoba students a look into a health sciences career
The students take part in a heart dissection as part of the Biomedical Youth Program Summer Camp on July 23, 2025. (Jamie Dowsett/CTV News) The University of Manitoba is giving young people a glimpse into what a career in health sciences would look like. This week the university is hosting its Biomedical Youth Program Summer Camp, which gives 100 students from Grades 6 to 12 a chance to take part in hands-on learning in the fields of medicine, dentistry, pharmacy, nursing and science. Activities include heart dissection, fingerprint analysis and DNA extraction. This year's camp also includes sessions on traditional Indigenous medicines. James Gilchrist, a professor in the department of oral biology, said the camp is meant to inspire kids and raise their curiosity about science. 'It's important that kids are informed and be able to make choices about what they may do as a future career,' he said. 'We have an emphasis upon biomedical matters and health sciences careers.' Kevin Wang, one of the students attending the camp, said the experience has made him interested in pursuing a career in the biomedical field in the future. He said his favourite part of the camp so far has been learning about gel electrophoresis. 'It's [basically] splitting the DNA into different parts,' he explained. 'Then we get to compare different DNA and find relationships.' The weeklong camp is run by U of M volunteers made up of undergraduate and graduate students. 'We have this motto of youth inspiring youth,' Gilchrist said. 'So we use graduate students and undergraduate students as a model for what you could become.'
Yahoo
22-05-2025
- Health
- Yahoo
Laureate Announced for Hamm International Prize for Diabetes Research
Honoree has made outstanding contributions toward understanding the pathogenesis and prevention of Type 1 diabetes OKLAHOMA CITY, May 22, 2025 /PRNewswire/ -- The prestigious Harold Hamm International Prize for Biomedical Research in Diabetes, an honor bestowed by OU Health Harold Hamm Diabetes Center at the University of Oklahoma Health Sciences, will be awarded this fall to Professor Dr. Anette-Gabriele Ziegler, Director of the Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health. She is also Chair in Diabetes and Gestational Diabetes at Technische Universität München, School of Medicine. She is being honored for her research to understand the pathogenesis of Type 1 diabetes and efforts toward its prediction, early diagnosis and prevention. The Hamm Prize recognizes and encourages lasting advances in research related to Type 1 or Type 2 diabetes. It is awarded to an individual who has either demonstrated lifelong contributions to the field or realized a singular advance, especially one that promotes curative potential. The honor includes a $250,000 award, the largest of its kind in the world. It was established to recognize and promote lasting achievements in diabetes research focused on progress toward a cure. "The award is an incredible motivation to look ahead and continue on the path toward understanding the pathogenesis of Type 1 diabetes and developing preventive therapies – with the ultimate goal of finding a cure," Ziegler said. The prize, established in 2012, is named for Harold Hamm, chairman and chief executive officer of Oklahoma-based Continental Resources Inc., who provided an endowment to fund the prize in perpetuity. The Hamm Prize laureate is selected by a rotating jury of national and international leaders in the diabetes research community and is awarded every two years. "This prize honors work that changes the course of science – and Dr. Ziegler's research does exactly that. Her leadership in uncovering how Type 1 diabetes begins and how we might stop it before it starts is the kind of bold, life-changing progress this prize was meant to recognize. Her work fuels our hope – and brings us all one step closer to the cure," Hamm said. Ziegler's research has been at the forefront of translating important research questions into longitudinal studies, including more than 20 clinical trials, as well as implementing findings into public health. Her achievements include: Launched BabyDiab, the first birth cohort to study when and how Type 1 diabetes begins. Launched Fr1da, a public screening program to detect early signs of Type 1 diabetes, now a model for similar global efforts. Initiated and serves as speaker of GPPAD (Global Platform for the Prevention of Autoimmune Diabetes), a European platform to translate knowledge about disease pathogenesis into trials seeking to prevent Type 1 diabetes. More than 2,000 infants have been enrolled in GPPAD's clinical trials and screened for genetic risk of Type 1 diabetes. Conducted research that led to a landmark clinical trial resulting in Food and Drug Administration approval for teplizumab, the first immunotherapy drug shown to delay the onset of Type 1 diabetes in at-risk individuals. In addition, Ziegler has made the following research discoveries: Autoimmunity to insulin is a key starting point for Type 1 diabetes in children, and Type 1 diabetes susceptibility genes predispose for autoimmunity. Islet autoimmunity (when the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas) starts early in life, with a peak incidence around age 1 to 2. Children with two or more islet autoantibodies almost always develop diabetes. Respiratory viral infections in early life, including COVID-19, raise the risk of islet autoimmunity in genetically at-risk children. Early changes in blood sugar and immune activity appear to precede the onset of autoimmunity to insulin. A physician who conducts research, Ziegler said caring for patients has informed her career as a scientist. "My mentor always used to say, 'A researcher is the best doctor,'" she said. "I'm not sure if the reverse is true, but my daily work with people living with diabetes and my experience as a physician have certainly shaped my research. They have especially influenced my strong focus on translational research, clinical trials, and investigating the origins of the disease in humans." Ziegler will receive the Hamm Prize during a gala in October. Jed Friedman, Ph.D., director of Harold Hamm Diabetes Center, said Ziegler's distinguished research career has significantly advanced the aim of preventing Type 1 diabetes. "Professor Dr. Ziegler's visionary leadership and unwavering commitment have not only advanced scientific understanding but also paved the way for novel interventions that improve patient outcomes by delaying the onset of Type 1 diabetes," Friedman said. "Her work exemplifies the integration of rigorous research with compassionate clinical application, embodying the highest ideals of medical science. We are privileged to honor [her] for her unparalleled contributions to diabetes research and her enduring impact on public health." About the projectFor more information about the Harold Hamm International Prize for Biomedical Research in Diabetes, visit the prize website here. About the University of OklahomaFounded in 1890, the University of Oklahoma is a public research university with campuses in Norman, Oklahoma City and Tulsa. As the state's flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. In Oklahoma City, OU Health Sciences is one of the nation's few academic health centers with seven health profession colleges located on the same campus. OU Health Sciences serves approximately 4,000 students in more than 70 undergraduate and graduate degree programs spanning Oklahoma City and Tulsa and is the leading research institution in Oklahoma. For more information about OU Health Sciences, visit View original content to download multimedia: SOURCE University of Oklahoma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-05-2025
- Health
- Yahoo
Martin County Schools unveils new way of learning
MARTIN COUNTY, N.C. (WNCT) — Martin County Schools plans to introduce a new level of learning: The Operation Game 2.0. In the fall of this year, learning in several health, science, and anatomy-related courses will take on a new look with the Anatomage Table thanks to the Martin County Schools Career and Technical Education department. 'We are excited to make this amazing learning tool available to our Health Science 1 and 2 classes, Nursing Fundamentals, and Biomedical Technology classes,' CTE Director for Martin County Schools, Jason Wynne said. 'There are also opportunities to utilize the table in Animal Science and Vet Tech courses.' The Anatomage is an operating-bed-sized table that will provide a highly accurate, three-dimensional, and high-resolution view of anatomical structures. During a demonstration, students were able to see the depth and detail the table brings. 'The Anatomage Table bridges the gap between textbook learning and real-world application, preparing our students for future careers in healthcare with cutting-edge technology right here in our classroom,' Health Science instructor, Rebecca Revels said. 'Students in Health Science will have increased opportunities for engaged learning and are excited to get started.' Veteran Nursing Fundamentals teacher and Registered Nurse Vinya Ward said, 'The Anatomage Table will offer students in all areas of our Health Science program an incredible opportunity to virtually study human anatomy content being taught in the classroom. This will allow students to become more engaged and interactive by seeing organs in 3-D and have the opportunity to dissect nine different cadavers.' There will be training for instructors who will soon utilize the table. In the fall, the Career and Technical Education team hopes to use the Anatomage Table in many CTE classes. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
